PCI upgrades its German cold storage for clinical trials

PCI Pharma Services says that it has doubled the 2-8°C (35.6-46.4°F) capacity at its Berlin facility, as well as adding -20°C (-4°F) and -80°C (-112°F) storage, all in order to “keep pace with global industry trends” in clinical trial logistics and distribution. The additions recently passed regulatory inspections and are fully operational. Further, there are plans to add liquid nitrogen-based storage in a future Phase 2, set to begin in FY 2022.

Brian Keesee, VP and GM, global clinical operations and supply, comments: “These expanded capabilities and breadth of offerings will ensure that our global and mainland EU customers conducting clinical trials, particularly those in the DACH region of Austria, Germany, and Switzerland, have the support of a full-service solution, which the industry prefers, in a prime location with excellent transport hubs.”